Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 189.20
AVDL's Cash-to-Debt is ranked higher than
53% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AVDL: 189.20 )
Ranked among companies with meaningful Cash-to-Debt only.
AVDL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 9.51 Max: 189.2
Current: 189.2
0.08
189.2
Equity-to-Asset 0.17
AVDL's Equity-to-Asset is ranked lower than
87% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AVDL: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
AVDL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08  Med: 0.53 Max: 0.8
Current: 0.17
-0.08
0.8
Piotroski F-Score: 4
Altman Z-Score: 0.39
Beneish M-Score: -2.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -3.41
AVDL's Operating Margin % is ranked higher than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. AVDL: -3.41 )
Ranked among companies with meaningful Operating Margin % only.
AVDL' s Operating Margin % Range Over the Past 10 Years
Min: -1285  Med: -31.77 Max: 41.25
Current: -3.41
-1285
41.25
Net Margin % -27.68
AVDL's Net Margin % is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. AVDL: -27.68 )
Ranked among companies with meaningful Net Margin % only.
AVDL' s Net Margin % Range Over the Past 10 Years
Min: -1027.16  Med: -29.38 Max: 23.47
Current: -27.68
-1027.16
23.47
ROE % -77.51
AVDL's ROE % is ranked lower than
71% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. AVDL: -77.51 )
Ranked among companies with meaningful ROE % only.
AVDL' s ROE % Range Over the Past 10 Years
Min: -1103.89  Med: -25.52 Max: 87.66
Current: -77.51
-1103.89
87.66
ROA % -17.14
AVDL's ROA % is ranked higher than
64% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AVDL: -17.14 )
Ranked among companies with meaningful ROA % only.
AVDL' s ROA % Range Over the Past 10 Years
Min: -58.46  Med: -12.4 Max: 20.89
Current: -17.14
-58.46
20.89
ROC (Joel Greenblatt) % -215.03
AVDL's ROC (Joel Greenblatt) % is ranked higher than
59% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AVDL: -215.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVDL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1730.55  Med: -42.79 Max: 3856.65
Current: -215.03
-1730.55
3856.65
3-Year Revenue Growth Rate 181.10
AVDL's 3-Year Revenue Growth Rate is ranked higher than
97% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. AVDL: 181.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVDL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -52.4  Med: -0.1 Max: 181.1
Current: 181.1
-52.4
181.1
3-Year EPS without NRI Growth Rate -18.20
AVDL's 3-Year EPS without NRI Growth Rate is ranked lower than
69% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. AVDL: -18.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVDL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.2  Med: -19.6 Max: 89.5
Current: -18.2
-38.2
89.5
GuruFocus has detected 1 Warning Sign with Avadel Pharmaceuticals PLC $AVDL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVDL's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with AVDL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:NAS:AGEN, NAS:MRUS, NAS:PRTK, NAS:RXDX, NAS:TLGT, NAS:CNCE, NAS:OTIC, NAS:IDRA, NAS:MACK, NAS:BOLD, NAS:BSTC, NAS:ARNA, NAS:CCXI, NAS:AKBA, AMEX:BTX, NAS:CLDX, NAS:OMED, NAS:NSTG, NAS:NVAX, NAS:CRIS » details
Traded in other countries:AWK1.Germany,
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in drug delivery and formulation to develop safer and more efficacious pharmaceutical products to address unmet medical needs and reduce overall healthcare costs.

France-based Flamel Technologies focuses on improving the safety and convenience of existing drugs through its drug-delivery platforms. Flamel partners with pharma firms to develop controlled-release formulations of products in exchange for royalties. Its Micropump technology is designed to enhance small-molecule drugs, while the Medusa platform is intended for therapeutic proteins and peptides. Flamel's Micropump system is used in Coreg CR, a beta blocker marketed by GlaxoSmithKline.

Ratios

vs
industry
vs
history
Forward PE Ratio 34.48
AVDL's Forward PE Ratio is ranked lower than
73% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. AVDL: 34.48 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 9.58
AVDL's PB Ratio is ranked lower than
82% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AVDL: 9.58 )
Ranked among companies with meaningful PB Ratio only.
AVDL' s PB Ratio Range Over the Past 10 Years
Min: 1.84  Med: 5.13 Max: 71.87
Current: 9.58
1.84
71.87
PS Ratio 2.69
AVDL's PS Ratio is ranked higher than
85% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. AVDL: 2.69 )
Ranked among companies with meaningful PS Ratio only.
AVDL' s PS Ratio Range Over the Past 10 Years
Min: 2.03  Med: 5.5 Max: 843.89
Current: 2.69
2.03
843.89
Price-to-Free-Cash-Flow 23.05
AVDL's Price-to-Free-Cash-Flow is ranked higher than
54% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. AVDL: 23.05 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AVDL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.54  Med: 21.95 Max: 154.15
Current: 23.05
4.54
154.15
Price-to-Operating-Cash-Flow 21.50
AVDL's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. AVDL: 21.50 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AVDL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.44  Med: 19.02 Max: 51.48
Current: 21.5
4.44
51.48
EV-to-EBITDA 31.41
AVDL's EV-to-EBITDA is ranked lower than
68% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. AVDL: 31.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVDL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -314.7  Med: -11.5 Max: 76.3
Current: 31.41
-314.7
76.3
Current Ratio 2.90
AVDL's Current Ratio is ranked lower than
62% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AVDL: 2.90 )
Ranked among companies with meaningful Current Ratio only.
AVDL' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.89 Max: 6.76
Current: 2.9
0.83
6.76
Quick Ratio 2.85
AVDL's Quick Ratio is ranked lower than
59% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AVDL: 2.85 )
Ranked among companies with meaningful Quick Ratio only.
AVDL' s Quick Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.83 Max: 6.7
Current: 2.85
0.77
6.7
Days Inventory 107.74
AVDL's Days Inventory is ranked higher than
58% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. AVDL: 107.74 )
Ranked among companies with meaningful Days Inventory only.
AVDL' s Days Inventory Range Over the Past 10 Years
Min: 51.05  Med: 87.9 Max: 1457.72
Current: 107.74
51.05
1457.72
Days Sales Outstanding 43.34
AVDL's Days Sales Outstanding is ranked higher than
64% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. AVDL: 43.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVDL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.7  Med: 69.78 Max: 541.87
Current: 43.34
14.7
541.87
Days Payable 188.78
AVDL's Days Payable is ranked higher than
81% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. AVDL: 188.78 )
Ranked among companies with meaningful Days Payable only.
AVDL' s Days Payable Range Over the Past 10 Years
Min: 180.56  Med: 245.25 Max: 3311.63
Current: 188.78
180.56
3311.63

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
AVDL's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. AVDL: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVDL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47.7  Med: -7.8 Max: -0.5
Current: -17.3
-47.7
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 486.50
AVDL's Price-to-Tangible-Book is ranked lower than
100% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. AVDL: 486.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVDL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.39  Med: 4.64 Max: 577.22
Current: 486.5
1.39
577.22
Price-to-Intrinsic-Value-Projected-FCF 5.15
AVDL's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
59% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. AVDL: 5.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AVDL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.77  Med: 7.52 Max: 8.98
Current: 5.15
4.77
8.98
Price-to-Median-PS-Value 0.49
AVDL's Price-to-Median-PS-Value is ranked higher than
82% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. AVDL: 0.49 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVDL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.9 Max: 16.16
Current: 0.49
0.43
16.16
Earnings Yield (Greenblatt) % -2.64
AVDL's Earnings Yield (Greenblatt) % is ranked higher than
66% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AVDL: -2.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVDL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.01  Med: 23.85 Max: 38.9
Current: -2.64
-3.01
38.9

More Statistics

Revenue (TTM) (Mil) $150.2
EPS (TTM) $ -1.00
Beta1.95
Short Percentage of Float0.91%
52-Week Range $8.61 - 15.45
Shares Outstanding (Mil)41.37

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 182 165
EPS ($) 0.27 0.37
EPS without NRI ($) 0.27 0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AVDL

Headlines

Articles On GuruFocus.com

More From Other Websites
AVADEL PHARMACEUTICALS PLC Files SEC form 10-K, Annual Report Mar 28 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 17 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Amendment or Waiver to Code of Ethics, Financial... Mar 07 2017
Avadel tops Street 4Q forecasts Mar 07 2017
Avadel tops Street 4Q forecasts Mar 07 2017
Avadel Pharmaceuticals Announces $25 Million Share Repurchase Program Mar 07 2017
Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results Mar 07 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events Mar 02 2017
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences Mar 02 2017
Avadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3% Feb 24 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events Feb 16 2017
Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results Feb 14 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events Feb 06 2017
Avadel Pharmaceuticals to Present at Two Upcoming Investor Conferences Feb 06 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events Jan 06 2017
AVADEL PHARMACEUTICALS PLC Financials Jan 06 2017
AVADEL PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2017
CORRECTING and REPLACING – Avadel Pharmaceuticals Provides 2017 Guidance and Business Update Jan 05 2017
Avadel Pharmaceuticals Provides 2017 Guidance and Business Update Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)